tizanidine has been researched along with Cerebral Palsy in 11 studies
tizanidine: RN given refers to parent cpd; structure
tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.
Cerebral Palsy: A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cerebral palsy is usually spastic, and baclofen, benzodiazepines and tizanidine are considered as oral treatments." | 9.13 | [Protocol for tizanidine use in infantile cerebral palsy]. ( Arroyo Riaño, O; Benavente Valdepeñas, A; Palazón García, R, 2008) |
| " Following botulinum toxin A treatment, clinical improvement led to the gradual reduction of baclofen or tizanidine dosing to one-third of the former dose." | 5.43 | Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity. ( Aksoy, SN; Dai, AI; Demiryürek, AT, 2016) |
| "Cerebral palsy is usually spastic, and baclofen, benzodiazepines and tizanidine are considered as oral treatments." | 5.13 | [Protocol for tizanidine use in infantile cerebral palsy]. ( Arroyo Riaño, O; Benavente Valdepeñas, A; Palazón García, R, 2008) |
| "For localized/segmental spasticity, botulinum toxin type A is established as an effective treatment to reduce spasticity in the upper and lower extremities." | 2.46 | Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child ( Aisen, M; Ashwal, S; Delgado, MR; Fehlings, DL; Hirtz, D; McLaughlin, J; Morrison, LA; Shrader, MW; Tilton, A; Vargus-Adams, J, 2010) |
| "While in some children, spasticity may adversely impact the motor abilities, in others, it may help maintain posture and ability to ambulate." | 2.43 | Pharmacologic interventions for reducing spasticity in cerebral palsy. ( Patel, DR; Soyode, O, 2005) |
| " Following botulinum toxin A treatment, clinical improvement led to the gradual reduction of baclofen or tizanidine dosing to one-third of the former dose." | 1.43 | Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity. ( Aksoy, SN; Dai, AI; Demiryürek, AT, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, AI | 2 |
| Aksoy, SN | 1 |
| Demiryürek, AT | 1 |
| Wasay, M | 1 |
| Awan, S | 1 |
| Delgado, MR | 1 |
| Hirtz, D | 1 |
| Aisen, M | 1 |
| Ashwal, S | 1 |
| Fehlings, DL | 1 |
| McLaughlin, J | 1 |
| Morrison, LA | 1 |
| Shrader, MW | 1 |
| Tilton, A | 1 |
| Vargus-Adams, J | 1 |
| Chung, CY | 1 |
| Chen, CL | 1 |
| Wong, AM | 1 |
| Patel, DR | 1 |
| Soyode, O | 1 |
| Palazón García, R | 1 |
| Benavente Valdepeñas, A | 1 |
| Arroyo Riaño, O | 1 |
| Knutsson, E | 1 |
| Shumilina, AP | 1 |
| Guzeva, VI | 1 |
| Skoromets, AA | 1 |
| Maksimov, OG | 1 |
| Secheĭko, MV | 1 |
| Andriĭchuk, EL | 1 |
| Brin, IL | 1 |
| Kurenkov, AL | 1 |
| Gotlib, VIa | 1 |
| Autti-Rämö, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Radial Extracorporeal Shock Wave Therapy for Management of Spasticity in Patients With Cerebral Palsy[NCT05702606] | 73 participants (Actual) | Interventional | 2021-06-10 | Completed | |||
| Sensory-Motor Rehabilitation Post Stroke[NCT02369770] | 140 participants (Anticipated) | Interventional | 2019-04-26 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for tizanidine and Cerebral Palsy
| Article | Year |
|---|---|
Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child
Topics: Adolescent; Botulinum Toxins, Type A; Cerebral Palsy; Child; Clonidine; Diazepam; Humans; Muscle Rel | 2010 |
Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child
Topics: Adolescent; Botulinum Toxins, Type A; Cerebral Palsy; Child; Clonidine; Diazepam; Humans; Muscle Rel | 2010 |
Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child
Topics: Adolescent; Botulinum Toxins, Type A; Cerebral Palsy; Child; Clonidine; Diazepam; Humans; Muscle Rel | 2010 |
Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child
Topics: Adolescent; Botulinum Toxins, Type A; Cerebral Palsy; Child; Clonidine; Diazepam; Humans; Muscle Rel | 2010 |
Pharmacotherapy of spasticity in children with cerebral palsy.
Topics: Baclofen; Benzodiazepines; Cerebral Palsy; Child; Clonidine; Dantrolene; Humans; Muscle Spasticity; | 2011 |
Pharmacologic interventions for reducing spasticity in cerebral palsy.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Age Factors; Anti-Infective Agents, Local; Baclofen | 2005 |
[Treatment of spasticity].
Topics: Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Clonidine; Humans; Injections, Spinal; Muscle Re | 1999 |
4 trials available for tizanidine and Cerebral Palsy
| Article | Year |
|---|---|
Botulinum toxin type A with oral baclofen versus oral tizanidine: a nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity.
Topics: Administration, Oral; Adolescent; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Chi-Square Dis | 2008 |
[Protocol for tizanidine use in infantile cerebral palsy].
Topics: Cerebral Palsy; Child; Child, Preschool; Clonidine; Drug Administration Schedule; Female; Humans; In | 2008 |
[The use of sirdalud in the treatment of spasticity in infantile cerebral palsy].
Topics: Adolescent; Anticonvulsants; Cerebral Palsy; Child; Child, Preschool; Clonidine; Dose-Response Relat | 1999 |
[The use of sirdalud in cerebral palsy in children].
Topics: Adolescent; Cerebral Palsy; Child; Clonidine; Dose-Response Relationship, Drug; Electromyography; Fe | 1999 |
3 other studies available for tizanidine and Cerebral Palsy
| Article | Year |
|---|---|
Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity.
Topics: Administration, Oral; Adolescent; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Child; Child, | 2016 |
Analysis of gait and isokinetic movements for evaluation of antispastic drugs or physical therapies.
Topics: Cerebral Palsy; Clonidine; Electromyography; Gait; Humans; Motor Neurons; Muscle Contraction; Muscle | 1983 |
[Sirdalud in the practice of the pediatric neurologist].
Topics: Adolescent; Cerebral Palsy; Child; Clonidine; Drug Evaluation; Humans; Muscle Relaxants, Central; Mu | 1997 |